查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611201

非类固醇消炎剂市场规模、份额、趋势分析报告：按适应症、给药途径、分销管道、地区和细分市场预测，2025-2030年

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

非类固醇消炎剂市场成长及趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球非类固醇消炎剂市场规模将达到312.9亿美元，2025年至2030年复合年增长率为5.66%。非类固醇消炎剂是主要用于缓解发炎和疼痛以及降低体温的药物。非类固醇消炎剂（NSAID）旨在缓解经痛、头痛、发烧、关节炎、扭伤、拉伤和其他慢性疼痛等症状，其普及率很高，预计将在预测期内推动市场发展。

由于全球目标疾病和慢性疼痛的盛行率上升以及这些疾病在老年人群中的高盛行率等因素，非类固醇消炎剂市场出现了成长机会。此外，对非处方非类固醇抗发炎药的需求不断增加，以及治疗头痛、偏头痛和月经痛的非类固醇抗发炎药的使用不断增加，预计也将推动预测期内的成长。

此外，关节炎和其他疼痛相关疾病的日益普及也有望支持成长。例如，英国、法国和德国的骨关节炎盛行率高于其他欧洲国家。体力活动较多的人关节炎的盛行率较低，且预期盛行率会随着年龄的增长而增加。因此，关节炎盛行率的上升预计也将促进预测期内的成长。

主要市场参与企业正在采取策略性倡议，例如地理扩张和采用非类固醇消炎剂组合药物，以增加市场占有率。例如，Alkem Labs 和 Dr. Reddy's Laboratories Ltd 正在美国销售非类固醇消炎剂。此外，用于治疗疼痛和其他发炎性疾病的非处方药的核准增加预计也将推动预测期内的成长。因此，由于主要企业采取的各种策略，市场可能会促进成长。

不同地区的政府正在采取措施减轻偏头痛、关节炎和其他疾病的负担，以利于他们自己。例如，美国国立卫生研究院推出了 HEAL，以加速改善疼痛和发炎性疾病管理的研究工作。此外，以患者为中心的结果研究所已采取倡议引入非阿片类药物治疗疼痛的选择。预计这些措施将在预测期内促进成长。

非类固醇消炎剂市场报告亮点

  • 2024 年，由于关节炎在全球范围内的高盛行率，关节炎细分市场将主导非类固醇抗发炎药物市场。
  • 零售药局领域占最大份额，预计在预测期内将保持其主导地位。
  • 由于全部区域疼痛及相关疾病的高发病率、大量患者以及不断增加的老年人口等因素，预计亚太地区在预测期内将以显着的复合年增长率增长。
  • 由于关节炎的高发病率、主要市场参与企业的存在以及该地区研究活动的增加，北美将在 2024 年占据市场主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章非类固醇消炎剂市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 非类固醇消炎剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章非类固醇消炎剂市场：按适应症预测及趋势分析

  • 细分仪表板
  • 非类固醇消炎剂市场：适应疾病变异分析
  • 按适应症分類的非类固醇消炎剂市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 关节炎
  • 偏头痛
  • 眼科疾病
  • 其他的

第五章非类固醇消炎剂市场：依给药途径估算及趋势分析

  • 细分仪表板
  • 非类固醇消炎剂市场：给药途径变异分析
  • 按给药途径分類的非类固醇消炎剂市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 口服
  • 局部的
  • 其他的

第六章非类固醇消炎剂市场：依通路估算及趋势分析

  • 细分仪表板
  • 非类固醇消炎剂市场：通路波动分析
  • 非类固醇消炎剂按分销管道的市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章非类固醇消炎剂市场：区域、估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 2024 年企业市场占有率分析
  • 主要企业简介
    • Pfizer Inc.
    • Bayer AG
    • GSK plc
    • Dr. Reddy's Laboratories Ltd
    • Viatris Inc
    • Teva Pharmaceutical Industries Ltd.
    • Johnson And Johnson Services, Inc.
    • Merck &Co., Inc.
Product Code: GVR-4-68039-952-5

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

The global non-steroidal anti-inflammatory drugs market size is estimated to reach USD 31.29 billion by 2030, registering a CAGR of 5.66% from 2025 to 2030, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.

The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy's Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.

Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

  • In 2024, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe
  • The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period
  • Asia Pacific region is expected to grow at a significant CAGR during the forecast period, owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region
  • North America dominated the market in 2024, due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease Indication
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Chronic Pain and Inflammatory Diseases
      • 3.2.1.2. Increase in geriatric population
      • 3.2.1.3. Awareness and Accessibility of OTC NSAIDs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Side Effects
      • 3.2.2.2. Competition from Alternative Therapies
  • 3.3. Non-Steroidal Anti-Inflammatory Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Movement Analysis
  • 4.3. Non-Steroidal Anti-Inflammatory Drugs Market by Disease Indication (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Arthritis
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Migraine
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Ophthalmic Diseases
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Movement Analysis
  • 5.3. Non-Steroidal Anti-Inflammatory Drugs Market by Route of Administration Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Oral
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Topical
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Non-Steroidal Anti-Inflammatory Drugs Market by Distribution Channel Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
  • 6.5. Hospital Pharmacy
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Retail Pharmacy
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Online Pharmacy
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Non-Steroidal Anti-Inflammatory Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. GSK plc
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Dr. Reddy's Laboratories Ltd
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Viatris Inc
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Teva Pharmaceutical Industries Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Johnson And Johnson Services, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Merck & Co., Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 4. North America NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 5. North America NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 6. North America NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 7. U.S. NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 8. U.S. NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 9. U.S. NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 10. Canada NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 11. Canada NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 12. Canada NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 13. Mexico NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 14. Mexico NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 15. Mexico NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 16. Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 17. Europe NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 18. Europe NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 19. Europe NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 20. UK NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 21. UK NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 22. UK NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 23. Germany NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 24. Germany NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 25. Germany NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 26. France NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 27. France NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 28. France NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 29. Spain NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 30. Spain NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 31. Spain NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 32. Italy NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 33. Italy NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 34. Italy NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 35. Denmark NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 36. Denmark NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 37. Denmark NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 38. Sweden NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 39. Sweden NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 40. Sweden NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Norway NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 42. Norway NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 43. Norway NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Japan NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 49. Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 50. Japan NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 51. China NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 52. China NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 53. China NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 54. India NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 55. India NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 56. India NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 57. South Korea NSAIDs Market, By disease indication 2018 - 2030 (USD Million)
  • Table 58. South Korea NSAIDs Market, By route of administration 2018 - 2030 (USD Million)
  • Table 59. South Korea NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 60. Australia NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 61. Australia NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 62. Australia NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 63. Thailand NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 64. Thailand NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 65. Thailand NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 66. Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 67. Latin America NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 68. Latin America NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 69. Latin America NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Brazil NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 71. Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 72. Brazil NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 73. Argentina NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 74. Argentina NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 75. Argentina NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 76. Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 77. Middle East & Africa NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 78. Middle East & Africa NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 79. Middle East & Africa NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 80. South Africa NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 81. South Africa NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 82. South Africa NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 83. Saudi Arabia NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 84. Saudi Arabia NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 85. Saudi Arabia NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 86. UAE NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 87. UAE NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 88. UAE NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 89. Kuwait NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 90. Kuwait NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 91. Kuwait NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 non-steroidal anti-inflammatory drugs market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 NSAIDs market: Disease indication outlook and key takeaways
  • Fig. 10 NSAIDs market: Disease indication movement analysis
  • Fig. 11 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 12 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 NSAIDs market: Route of administration outlook and key takeaways
  • Fig. 16 NSAIDs market: Route of administration movement analysis
  • Fig. 17 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 NSAIDs market: Distribution channel outlook and key takeaways
  • Fig. 21 NSAIDs market: Distribution channel movement analysis
  • Fig. 22 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 North America non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 US non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Canada non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Europe non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 UK non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Germany non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 France non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Italy non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Spain non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Sweden non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Norway non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Asia Pacific non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Japan non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 China non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 India non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Australia non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Thailand non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Argentina non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 MEA non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Saudi Arabia non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UAE non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Kuwait non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 List of key emerging company's/disruptors/innovators